MarketCap
Facebook
X
TelegramAnnual report 2022
added 12-21-2024
ERYTECH Pharma S.A. General and Administrative Expenses 2011-2026 | ERYP
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses ERYTECH Pharma S.A.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 15.6 M | 14.3 M | 16.4 M | 14.6 M | 8.52 M | 6.66 M | 7.62 M | 4.36 M | 3.55 M | 3.3 M | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.4 M | 3.3 M | 9.49 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
ACADIA Pharmaceuticals
ACAD
|
488 M | $ 22.56 | 2.13 % | $ 3.74 B |  USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
argenx SE
ARGX
|
308 M | $ 785.07 | 2.57 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | France |
 |
Akebia Therapeutics
AKBA
|
107 M | $ 1.43 | 3.62 % | $ 368 M | USA |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.21 B | $ 327.25 | 2.42 % | $ 42.9 B | USA |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.9 | 3.7 % | $ 9.38 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
132 M | $ 1.49 | 9.56 % | $ 397 M | Britain |
 |
AVROBIO
AVRO
|
24 M | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Aquestive Therapeutics
AQST
|
79.8 M | $ 4.18 | 1.21 % | $ 447 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
17.4 M | $ 2.66 | 3.5 % | $ 16.7 M | USA |
 |
AstraZeneca PLC
AZN
|
15.2 B | - | - | $ 96.9 B | Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
5.78 M | - | -2.5 % | $ 5.88 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
275 M | $ 24.61 | 5.76 % | $ 3.13 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Cabaletta Bio
CABA
|
29.6 M | $ 3.09 | 0.65 % | $ 310 M | USA |
 |
CymaBay Therapeutics
CBAY
|
52 M | - | - | $ 3.45 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
Codiak BioSciences
CDAK
|
27.6 M | - | -55.98 % | $ 2.15 M | USA |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
20.6 M | - | - | $ 1.41 B | USA |
 |
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Celldex Therapeutics
CLDX
|
43.8 M | $ 32.41 | 3.38 % | $ 2.15 B | USA |
 |
Celsion Corporation
CLSN
|
6.87 M | - | -6.63 % | $ 13.9 M | USA |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Chimerix
CMRX
|
24.6 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
22.5 M | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
9.28 M | $ 3.88 | 2.11 % | $ 261 B | Britain |